Skepta and PUMA Launch Groundbreaking Collection 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
ECB Calls for Monitoring and Possible Regulation of AI in Finance 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
PUMA Welcomes AC Milan Star Theo Hernández to the Family 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
How supermarkets are changing their branding to make you think they’re cheaper 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
Shanghai's Data Policy Shift Could Propel Tesla's Local Data Center Efforts 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
REDWOOD CITY, Calif., Feb. 23, 2016 -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that the company plans to present at the Cowen and Company 36th Annual Health Care Conference in Boston.
Avinger management is scheduled to present on Tuesday, March 8, 2016 at 8:40am ET. Interested parties can access the live audio webcast with accompanying slides from the Events section of Avinger's website at www.avinger.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.
About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral arterial disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current lumivascular products include the Lightbox™ imaging console, the Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit www.avinger.com.
"Avinger," “Pantheris” and the Avinger logo are registered trademarks of Avinger, Inc.
Investor Contact: Leigh Salvo Westwicke Partners Phone: +1 415 513 1281 Email: [email protected]
